Publications by authors named "Pratik Devasthale"

Claim this Profile
D
Discovery of (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders.
Wei Meng, Robert Brigance, James Mignone, Lidet Negash, Guohua Zhao, Pratik Devasthale

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
Fang Moore, Wei Wang, Guohua Zhao, James Mignone, Wei Meng, Pratik Devasthale

Bioorg Med Chem Lett· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.
Dong Cheng, Bradley A Zinker, Yi Luo, Petia Shipkova, Claudia H De Oliveira, Pratik Devasthale

Cell Metab· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
Huji Turdi, Hannguang Chao, Jon J Hangeland, Saleem Ahmad, Wei Meng, Pratik Devasthale

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
Pratik Devasthale, Dong Cheng

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies.
Pratik Devasthale, Wei Wang, James Mignone, Kishore Renduchintala, Sridhar Radhakrishnan

Bioorg Med Chem Lett· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup.
Pratik Devasthale, Wei Wang, Andres S Hernandez, Fang Moore, Kishore Renduchintala

Bioorg Med Chem Lett· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.
Hao Zhang, Charles Z Ding, Zhi Lai, Sean S Chen, Pratik Devasthale

Bioorg Med Chem Lett· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
William N Washburn, Mark Manfredi, Pratik Devasthale, Guohua Zhao, Saleem Ahmad

J Med Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
Pratik Devasthale, Ying Wang, Wei Wang, John Fevig, JianXin Feng

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Wei Wang, Pratik Devasthale, Aiying Wang, Tom Harrity, Don Egan

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Jun Li, Lawrence J Kennedy, Yan Shi, Shiwei Tao, Xiang-Yang Ye, Pratik V Devasthale

J Med Chem· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Hao Zhang, Denis E Ryono, Pratik Devasthale, Wei Wang, Kevin O'Malley

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Wei Wang, Pratik Devasthale, Dennis Farrelly, Liqun Gu, Thomas Harrity

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
Effie Tozzo, Randolph Ponticiello, JoAnn Swartz, Dennis Farrelly, Rachel Zebo, Pratik Devasthale

J Pharmacol Exp Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
Pratik V Devasthale, Sean Chen, Yoon Jeon, Fucheng Qu, Denis E Ryono

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Thomas Harrity, Dennis Farrelly, Aaron Tieman, Cuixia Chu, Lori Kunselman, Pratik Devasthale

Diabetes· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Pratik V Devasthale, Sean Chen, Yoon Jeon, Fucheng Qu, Chunning Shao

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chiral DNA gyrase inhibitors. 3. Probing the chiral preference of the active site of DNA gyrase. Synthesis of 10-fluoro-6-methyl-6,7-dihydro-9-piperazinyl- 2H-benzo[a]quinolizin-20-one-3-carboxylic acid analogues.
Robert A Fecik, Pratik Devasthale, Segaran Pillai, Ali Keschavarz-Shokri, Linus Shen

J Med Chem· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
Jon J Hangeland, Arthur M Doweyko, Tamara Dejneka, Todd J Friends, Pratik Devasthale

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis